Merck’s NuvaRing is expected to reach blockbuster status in 2012, meaning millions of women across the country trust and use it. However, medical journal findings continue to indicate that dangerous blood clot side effects are strongly associated with its use. Non-oral hormonal contraception like NuvaRing can be more convenient for women who don’t want to remember to take a pill every day, but that convenience comes at a price.
Close to five million NuvaRing prescriptions were written in the U.S. in 2010, but serious questions have come up in scientific literature this year concerning its safety. Approximately 1,000 cases of possible NuvaRing-related blood clots have been reported to the FDA. In addition, over 900 American women have already filed NuvaRing lawsuits against Merck for downplaying its dangerous side effects.
The contraceptive ring, while effective for birth control, comes along with an increased risk for venous thromboembolism (VTE). The etonogestrel-containing vaginal ring has serum concentrations of sex hormone binding globulin higher than combination oral contraceptive pills. At least one study found NuvaRing had a 90% higher risk of venous thrombosis than did combined oral contraceptives containing levonorgestrel, bringing the ring’s risk to the same level as that of Yaz/Yasmin.
The transvaginal ring has now been medically linked multiple times to an increase in the risk for deep vein thrombosis, pulmonary embolism, ischemic stroke, and death. Recent medical literature indicates that while birth control pills can vary in both what they contain and what the associated risks are, the VTE risk for non-oral contraceptives like NuvaRing and OrthoEvra is equivalent to the highest risk, as seen in the Yaz and Yasmin products of the third or fourth generation.
The lawyers of Watts Guerra Craft LLP are accepting NuvaRing cases for blood-clot side effects such as pulmonary embolism (PE), deep vein thrombosis (DVT), ischemic stroke (CVA), and death associated with NuvaRing use.
The federal litigation over NuvaRing is currently consolidated for pretrial proceedings before U.S. District Judge Rodney Sippel in the Eastern District of Missouri as part of an MDL, or multidistrict litigation. The NuvaRing MDL case is In re: NuvaRing Products Liability Litigation, No. 08-md-1964.